Jpmorgan Chase & Co »

Rapport Therapeutics shares owned by Jpmorgan Chase & Co

Quarter-by-quarter ownership of Rapport Therapeutics (RAPP) shares owned by Jpmorgan Chase & Co from 13F filings

Historical chart of Jpmorgan Chase & Co investment in Rapport Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Rapport Therapeutics held by Jpmorgan Chase & Co consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Rapport Therapeutics by Jpmorgan Chase & Co

Quarter filed Position value Share count Share price at filing
2024-09-30 $83k 4.0k 20.48

More positions owned by Jpmorgan Chase & Co

Microsoft Corp Common (MSFT)
Nvidia Corporation Common (NVDA)
Apple Common (AAPL)
Amazon Common (AMZN)
Spdr S&p 500 Etf Ser 1 S&p Common (SPY)
Meta Platforms Common (META)
Eli Lilly & Co Common (LLY)
Alphabet Common (GOOG)
Unitedhealth Group Common (UNH)
Mastercard Incorporated Common (MA)
Vanguard Index Fds S&p 500 Etf Common (VOO)
Ishares Core S&p 500 Etf Fund (IVV)
Vanguard Total Intl Bond Etf Fund (BNDX)
Broadcom Common (AVGO)
Exxon Mobil Corp Common (XOM)

View all positions for Jpmorgan Chase & Co

Top funds holding Rapport Therapeutics

Arch Venture Corp
Cormorant Asset Management
Capital Research and Management Company - Division 3
Johnson & Johnson
Sofinnova Ventures
T. Rowe Price Investment Management
Alliancebernstein
T. Rowe Price Associates
Perceptive Advisors
BlackRock
Citadel Advisors
Siren
Logos Global Management
Geode Capital Management
Woodline Partners

View all funds holding Rapport Therapeutics